The key results are outlined in Figure 10 and described below
Some of the advertisers who received letters have already removed the specific offending language
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, reduces appetite by signaling fullness to the brain and slowing stomach emptying
Selain itu, semaglutide juga mengurangi rasa lapar dan keinginan makan, sehingga berkaitan dengan pengendalian makan yang lebih baik, porsi makan yang lebih kecil, dan penurunan intake energi.[3,6] Studi Wilding, et al
In contrast, 27% of respondents aged between 25-34 and 25% of respondents aged between 16-24 said they found it difficult to lose weight
Ozempic (up to 2 mg) is used to treat type 2 diabetes